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Abstract 
A retinoic acid (RA) inducible skin-specific gene transcript (RIS-1) was isolated by differential hybridization 
screening of a RA-treated human skin cDNA library. The library was constructed from pooled RNA derived 
fi'om normal adult human skin treated with all trans-RA for 4 h (n=6) and 12 h (n=6) in vivo. RIS-1 cDNA 
corresponded to a 0.6 kb transcript that was barely detectable in normal adult human skin but was significantly 
induced by 8 h in RA-treated compared to vehicle-treated skin (range 1.1-3.6 fold). Prolonged RA treatment for up 
to 24 h further increased relative RIS-1 mRNA levels by 1.3-5.5 fold. HPLC analysis of the RA content of 0.1% 
RA-treated skin in vivo revealed significant levels at 6 h (18.8-120.6 ng RA/g wet weight tissue; approximately 
240 nM), immediately preceding the time point at which the increased RIS-1 mRNA level was first seen. This 
concentration of RA also induced the mRNA levels for cellular RA binding protein II (1.6-19 fold), a marker of 
RA activity in human skin. RIS- 1 mRNA was detected by Northern and dot blotting only in normal skin but not in 
any other normal human tissues examined, indicating a tissue-specific pattern of gene expression. RIS-1 transcripts 
were detected at very low levels in untreated cultured human epidermal keratinocytes, while no expression was 
seen in dermal fibroblasts and melanocytes, the other major cell types in skin. Southern analysis of human and 
mouse DNA indicated the existence of evolutionarily conserved sequences for RIS-1 between these two species. 
The polypeptide sequence derived from the partial RIS-1 cDNA was found to be identical to the calcium binding 
domain found in 'psoriasin', a gene whose expression appears to be increased in the skin of psoriasis patients. 
Abbreviations." RIS-1 = _retinoic acid-inducible skin-specific gene; RA = All-trans retinoic acid. 
Introduction 
All-trans retinoic acid (RA) induces a characteristic set 
of biochemical and histological changes when applied 
to human skin [ 1] and is used topically to treat a variety 
of cutaneous diseases [2]. However, the cellular and 
molecular mechanism(s) by which topical RA treat- 
ment induces cutaneous changes is largely unknown. 
The recent discovery of two distinct families of nucle- 
ar RA receptors, the retinoic acid receptors (RAR) 
and the retinoid X receptors (RXR), has provided a 
possible explanation for the pleiotypic effects of RA 
in human skin [3, 4]. These receptors transcriptional- 
ly activate target genes by cooperative binding to the 
RA response element (RARE) [5]. The RARE, a spe- 
cific DNA sequence motif, or a closely related one, 
originally identified in the RAR-beta promoter, binds 
RAR/RXR heterodimers and is responsible for the RA- 
mediated activation of RA response genes. Due to their 
specific pattern of expression, it has been suggested 
that each RAR or RXR might have its own specif- 
ic function depending on the tissue and cell types in 
which they are expressed [6]. 
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We and others have demonstrated RAR and RXR 
gene expression in adult human skin and in cultured 
cells derived from human epidermis and dermis [7-9]. 
This expression is compatible with RAR/RXR media- 
tion of at least some RA regulation of gene expression 
in human skin. No variation has been found in the 
expression of the various RARs and one of the RXR 
isoforms in RA topically-treated skin in vivo [7-9], 
or cultured human keratinocytes in vitro [8], suggest- 
ing the possible involvement of additional cell or tissue 
specific factors in RA-mediated skin response. Another 
class of proteins known to be regulated by RA includes 
the family of cytosolic RA binding proteins, CRABP-I 
and II [ 10, 11]. We and others have recently shown that 
CRABP-II transcripts are expressed in adult human 
skin [12, 13]. CRABP-II mRNA is markedly induced 
in normal human skin [7], and mouse skin by topical 
RA and its synthetic analogs [14]. However, CRABP- 
II appears to regulate the amount of free RA available 
to activate RAR/RXR transcriptional activators [15], 
rather than directly mediating the effects of RA. 
Other RARE containing RA response genes include 
growth hormone [16], phosphoenolpyruvate car- 
boxykinase [17], Era-1/HOX 1.6 [18], and alco- 
hol dehydrogenase [19]. Although, these genes may 
have important functions in embryonic development, 
metabolic pathways and cellular homeostasis [for 
review see 20], they are either not expressed in adult 
human skin or are not responsive to topical RA. 
Therefore, the question of which genes are direct 
targets of RA action in skin and how this regulation is 
effected remains an important but unresolved issue. As 
an initial step towards identifying RA early response 
genes in skin, we have utilized the differential screen- 
ing of a cDNA library constructed from RA-treated 
human skin. We report here the cloning and charac- 
terization of a cDNA whose mRNA level increases 
rapidly within 6-8 h in RA-treated skin in vivo, indicat- 
ing that it represents a skin-specific early RA response 
gene. 
Materials and methods 
Adult human epidermal samples 
After obtaining informed consent, adjacent skin areas 
(9 x 3 cm) of the buttocks of healthy volunteers were 
treated for 4 h to 48 h with a single dose of approx- 
imately 500 mg RA cream (0.1% Retin A ®)  and its 
vehicle cream (Ortho Pharmaceutical Corp., Raritan, 
NJ) under occlusion with plastic wrap [1]. Keratome 
biopsies (0.2 mm thick) were then obtained under local 
anaesthesia with 1% lidocaine, immediately frozen in 
liquid nitrogen and stored at - 7 0  °C until use. The 
biopsies contained primarily 90-95% keratinocytes, 
the remaining cell types being melanocytes, fibrob- 
lasts, endothelial and Langerhans cells [1]. Proto- 
cols for human subjects were previously approved 
by the University of Michigan Institutional Review 
Board. 
Measurement of RA concentration in skin samples 
Prior to keratome biopsy, stratum corneum was 
removed by tape stripping of intact skin to avoid 
elevated RA amounts due to its trapping by stratum 
corneum. The extent of the removal of the stratum 
corneum was monitored by microscopic examination 
of parallel 4-mm punch specimens of tape-stripped 
skin as described [21]. The tape-stripped biopsies were 
weighed, powdered and immediately transferred into 
CHC13 :CH3 OH (2:1) containing tracer amounts of 3 H- 
RA (DuPont NEN, Boston, MA). After extraction, 
the RA content was analyzed by HPLC essentially as 
described [21]. Protein measurements were carried out 
by method of Lowry [22]. 
Cell cultures, RNA isolation. Northern & dot 
blotting 
Human dermal fibroblasts, epidermal keratinocytes 
and melanocytes were cultured as described [23]. 
Preparation of RNA from skin biopsies and cultured 
cells as well as Northern blotting were as previous- 
ly described [23]. The human multiple tissue RNA 
blot (MTN) was obtained from Clonetech Labora- 
tories (Cat. #7760-1, Palo Alto, CA). The dot blot 
was prepared, using a microsample filtration manifold 
(Schleicher and Schuell, Keene, NH) and manufac- 
turer's recommendations. All blots were hybridized 
with random-primed 32p-labeled cDNA probes [23] 
and RNA blots were quantitated after 24 h exposure 
using a PhosphorImager (Molecular Dynamics, Sun- 
nyvale, CA) [23]. As an internal control for quantita- 
tion of mRNA levels in RNA blots, a cDNA encod- 
ing the human acidic phosphoprotein PO (36B4) was 
simultaneously hybridized to all Northern blots [23]. 
36B4 is derived from epithelial MCF-7 cells and is 
believed to be under translational control [24]. In some 
experiments, cyclophilin cDNA [25] was used as con- 
trol gene. No differences were observed between 36B4 
and cyclophilin mRNA levels in either RA- or vehicle- 
treated skin. For RNA loading differences in dot blots, 
a cDNA probe corresponding to 3' untranslated region 
of 28S ribosomal RNA (pA4) [26] was used as con- 
trol. 
Library construction and differential screening 
Prior to poly (A) separation, equal amounts of total 
RNA was pooled from six individuals and from two 
different time points (4 and 12 h) to maximize represen- 
tation of different mRNA species in the library. Poly 
(A) RNA was then prepared using standard procedures 
[27], by one cycle of binding to oligo (dT)-cellulose 
column (Pharmacia, Uppsala, Sweden). 10 #g poly 
(A) RNA from the RA-treated skin was used to con- 
struct a cDNA library in EcoRI cut Lambda Zap II 
cloning vector according to Stratagene protocols (La 
Jolla, CA). The library contained 6.2 x 106 primary 
plaques with an estimated 4% nonrecombinants. The 
remainder of poly (A) from both the RA- and vehicle- 
treated control skin was converted into 32p-labeled 
single-stranded DNA probe by reverse transcription 
of mRNA as described [23, 27]. For screening, each 
radiolabeled probe was separately hybridized to each 
of the two replica filters (total of 20) prepared from 
the unamplified RA-treated library. Plaques showing 
different intensities of hybridization signal between 
the two probes were rescreened at lower densities and 
plaque purified by two subsequent differential screen- 
ing as described above. RIS-1 cDNA was rescued as 
a single-stranded DNA and converted into a circu- 
lar plasmid using procedures described in Stratagene's 
manual. Plasmids were propagated and cDNA inserts 
were released by EcoRI digestion using established 
techniques [27]. 
DNA sequencing 
RIS-1 cDNA was sequenced in both orientations and 
on both strands by dideoxy chain termination method 
[27], using the bluescript M13 reverse and M13- 
21 primers and Sequenase (United States Biochem- 
icals, Cleveland, OH), as described [7]. The partial 
nucleotide sequence was compared by the method of 
Pearson and Lipman with sequences entered in Gen- 
bank, release #71 and EMBL, release #30. 
Southern blotting 
Human DNA (Clonetech Laboratories) and mouse 
DNA (a gift from Dr. David Burke, University of 
Michigan) were digested with restriction enzymes as 
indicated in figure legends and DNA blots were pre- 
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pared using established protocols [27]. Southern blots 
were hybridized under conditions identical to those 
described for Northern blots [23], except for low strin- 
gency washes which were: 1) 2 x SSC, 0.1% SDS, at 
room temperature for 20 rain, 2) 0.2 x SSC, 0.1% SDS 
at 50 °C for 30 min. 
Statistical analysis 
Values obtained from RA- and vehicle-treated skin 
samples were normalized to the values of the 36B4 con- 
trol gene. The RA-treated values were then expressed 
as fold-change relative to vehicle-treated skin of the 
same individual for each time point. Because of the 
non-Gaussian distribution of the data, the median val- 
ues and the 25- and 75-percentiles were assessed in 
all groups of observations. The significance of dif- 
ferences in RIS-1 mRNA levels between RA- and 
vehicle-treated skin was determined by the two-tailed 
Wilcoxon matched pairs test. Significance for induc- 
tion ratios among time points for either RA- or 
vehicle-treated skin was ascertained by the two-tailed 
Mann-Whitney-U test and the Kruskal-Wallis test, as 
described [23]. 
Results 
Isolation of RIS-1 cDNA from RA-treated library 
20000 plaques from the unamplified RA-treated 
library were screened by differential hybridization with 
32P-labeled single-stranded DNA probes derived from 
RA- and vehicle-treated skin. Multiple plaques exhib- 
ited a differential hybridization signal between the two 
probes, and eleven were chosen for further investiga- 
tion. After two rounds of rescreening and plaque purifi- 
cation, three clones continued to show varying signal 
intensities (data not shown). One of these clones, RIS- 
1, was selected for further analysis. The 32p-labeled 
RIS-1 cDNA insert detected a 0.6 kb mRNA species 
whose levels were modestly increased in RA-treated 
human skin Northern blots. These blots had been previ- 
ously prepared from the same pooled RNA used to con- 
struct the RA-treated library. A subsequent screening 
of approximately 400 000 lambda clones from the RA- 
treated library, using RIS-1 as probe, resulted in iden- 
tification Of approximately 80 clones (0.02%). These 
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Fig. 1. Time course and kinetics of induction of RIS-I rnRNA in response to topical RA. (A) Volunteers were treated for indicated times 
with either vehicle cream (V) or 0.1% RA cream (R) under occlusion with plastic wrap, or left untreated (N). Total RNA (30 #g/lane) was 
hybridized simultaneously against random-primed 32p-labeled cDNA probes for RIS-1 and 36B4 control gene. A representative RNA blot 
showing control-matched RNA samples for two individuals from each time points is shown. Only the relevant portion of the blot is presented 
with the size of mRNA species indicated on the left; (B) Values denote RIS-1 levels normalized to the control gene, expressed as fold-induction 
relative to matched, vehicle-treated skin. The median and 25- and 75-percentile values are depicted (4 h, n = 6; 6 h, n = 6; 8 h, n = 6; 12 h, n = 6; 
24 h, n = 5; 48 h, n = 5; untreated normal skin, n = 5); (C) Integrated autoradiographic intensity of RA-treated and vehicle-treated skin from 'A' 
are shown separately as induction ratios after normalization to 36B4 mRNA levels The median and 25- and 75-percentile values are depicted. 
Kinetics and time course of RIS-I mRNA induction in 
human skin in vivo 
The kinetics and time course of induction of RIS-1 
mRNA was next examined by Northern blotting of 
R N A  from previously unexposed skin of additional 
volunteers treated with RA and its vehicle from 4 to 
48 h (Fig. 1A to 1C). Of six individuals treated with 
RA and vehicle for 4 h, RIS- 1 mRNA was undetectable 
in five but induced by 9-fold in only one RA-treated 
individual. A relative increase of 1.9 fold (range 0.5-  
5.4 fold, n = 6) in RIS-1 levels was seen by 6 h in 
RA-treated skin (Fig. 1B). RA treatment caused a sig- 
nificant increase in RIS-1 mRNA levels at 8 h (median 
2.2 fold, range 1.1-3.6; n---6, p=0.028) ,  12 h (2.2, 
1.6-5.8; n = 6 ,  p=0.028) ,  24 h (2.9, 1.3-5.5; n = 5 ,  
p = 0.043), but not at 48 h (median 3.1, range 0.8-7.5 
fold; n = 5, p = ns) compared to vehicle-treated skin. 
The magnitude of increase in RIS-1 mRNA levels 
varied considerably between individuals. When val- 
ues for RA-treated skin were normalized against the 
control gene, a marked temporal increase in RIS-1 
mRNA levels was seen in all samples beginning at 
8 h (Fig. 1C). Vehicle treatment alone did not induce a 
significant increase in RIS-1 transcript levels between 
6-24 h but stimulated a modest rise in RIS-1 mRNA 
levels at 48 h. This vehicle-mediated induction of RIS- 
1 mRNA levels at later time points offset the expected 
higher relative values for RIS-1 in skin treated with 
RA for 48 h (compare Fig. 1B & Fig. 1C). 
Induction of RIS-1 gene expression coincides with the 
presence of RA and increased CRABP-H mRNA levels 
in skin in vivo 
To determine whether RIS-1 activation was RA- 
dependent, we next analyzed the tissue concentrations 
of RA in skin in vivo by HPLC. Volunteers were treat- 
ed with RA or vehicle for 4, 6, 8 or 12 h spanning 
the time point (6-8 h) at which an increase in RIS-1 
mRNA was first detected. RA was undetectable in skin 
treated with vehicle alone at all time points. RA treat- 
ment significantly increased RA levels in skin at 6, 8 
and 12 h (p<0.02) (Fig. 2A). The earliest time point at 
which significant RA levels were detected (6 h, medi- 
an 56.5, range 18.8-120.6 ng RA/gm wet wt tissue; 
A 
200- 

















. J  
UJ "-- -IEi" . . . . . . . . . . .  
4 6 8 12 
RA TREATMENT (HOURS) 
Fig. 2. RIS-1 activation coincides with the presence of RA and 
induction of CRABP-II mRNA in RA-treated skirl in vivo. Vol- 
unteers were treated as described in legends to Fig. 1. The tissue 
samples were homogenized and examined: (A) by HPLC for RA 
content, and (B) by Northern blotting for CRABP-II mRNA levels 
RA concentration has been normalized to the gram wet weight of the 
tissue. The CRABP-II mRNA levels in RA-treated skin are normal- 
ized to the control gene cyclophilin and expressed as fold-induction 
relative to matched, vehicle-treated skin. The median and 25- and 
75-percentile values are depicted. 
n = 9, p = 0.02) immediately preceded the time point 
(8 h) at which a significant increase in RIS-1 mRNA 
levels was first seen (compare Fig. 1 and Fig. 2A). 
Because CRABP-II mRNA is markedly and specif- 
ically induced by topical RA in human skin [7, 9], and 
considered to be a marker of RA activity [28], we also 
measured CRABP-II mRNA levels at the time points 
indicated above. RA treatment significantly induced 
CRABP-II mRNA levels relative to vehicle-treated 
skin at 6 h (median 8.25 fold, range 1.6-19; n= 6), 
and at 8 h and 12 h (p<0.007) (Fig. 2B). 
Tissue and cell type specific expression of RIS-1 
We next examined the tissue specific pattern of RIS-1 
gene expression in RNA derived from several nor- 
mal human tissues. As depicted in Fig. 3A, RIS-1 
mRNA transcripts could not be detected in poly (A) 
RNA from any of the eight human tissues exam- 
ined, even after prolonged autoradiographic exposure 
of blots. A strong hybridization signal was detected 
in all samples for 36B4 mRNA used as the control 
gene (Fig. 3A). As expected, a blot containing RNA 
from RA- and vehicle-treated skin which was simulta- 
neously hybridized gave two bands of 0.6 and 1.3 kb, 
corresponding to RIS- 1 and 36B4 mRNA, respectively 
(Fig. 3A). 
To determine RIS-1 gene expression in cell types 
of human skin. RNA was extracted from untreated 
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cultured cells and analyzed by dot blot hybridization 
using RIS-1 as probe. Dot blot analysis demonstrated 
the presence of RIS- 1 transcripts in untreated normal 
skin. Normal untreated cultured keratinocytes in vitro 
showed very low level expression of RIS- 1 mRNA. No 
hybridization signal was apparent in dot-blotted RNA 
from cultured fibroblasts, melanocytes and a lympho- 
cyte cell line (IM-9) (Fig. 3B), or in a Northern blot of 
poly (A) RNA from RA-treated F9 cells (Dr. J. Grippo, 
Hoffmann-La Roche, Inc.) (data not shown). 
Identity of RIS-1 cDNA and its sequence 
conservation 
The single RIS-1 clone isolated was approximately 
209 nucleotides long. DNA sequencing of this cDNA 
showed an open reading frame of 49 amino acids 
followed by a TGA termination codon, a canonical 
AUAAA, and a long stretch of poly (A) tail at the 
C-terminus. Computer-assisted analysis of the derived 
49 amino acid sequence predicted a polypeptide of 
5.7 kDa. However, since RIS-1 cDNA clone does not 
appear to be full length, the actual size of the encoded 
protein will probably be larger. A search of gene data 
bank did not reveal homology between the sequence 
of RIS- 1 and other known RA-inducible genes. How- 
ever, RIS-1 sequence was found to exhibit homology 
to amino acids 54-102 of 'psoriasin', a gene reported- 
ly overexpressed in psoriatic epidermis [29]. The two 
regions of homology were identical except for a C - 
> T conversion at the nucleotide position 266 in pso- 
riasin (58 in RIS-1). The first 29 amino acids of RIS- 
1 also exhibited 44% homology to the EF-hand type 
calcium binding domain of calmodulin type [30]. To 
examine the genomic organization and sequence con- 
servation of RIS- 1 in mammalian species, a random- 
primed RIS-1 cDNA probe lacking PstI, HindIII and 
BamHI restriction sites was hybridized to the human 
and mouse genomic DNA digested with the corre- 
sponding enzymes. This revealed several hybridizing 
bands (Fig. 4), suggesting the existence of conserved 
RIS-l sequences in these species. 
Discussion 
This paper describes isolation of a cDNA representing 
an early retinoic acid-induced gene whose expression 
is restricted to skin (RIS-1). While the possible func- 
tion of RIS-1 in mediating cutaneous effects of RA can 

















Fig. 3. Restricted expression of RIS-1 mRNA in human tissues and cultured cells. (A) cDNA probes for RIS-1 and 36B4 were 32p-labeled to 
similar specific activity and simultaneously hybridized to 2.5 #g poly (A) RNA extracted from human tissues. As a positive control, a RNA blot 
prepared from vehicle-treated (1) and RA-treated (2) skin was also included in the hybridization (right panel). After simultaneous hybridization 
for 18 h, blots were washed under both low and high stringency and examined for RIS-1 and 36B4 gene expression; (B) Total RNA was 
isolated from untreated cultured human cells and 1 and 10/~g RNA was analyzed by dot blot hybridization to 32p-labeled RIS-1 insert. RNA 
from human skin and liver served as positive and negative controls, respectively. The cell types are indicated at the top: FB, fibroblasts; KC, 
keratinocytes; MC, melanocytes, and LC, IM-9 lymphocytes. After removal of RIS-1 probe, the filter was subsequently hybridized to a 28S 
ribosomal probe to determine equal RNA loading (lower panel in 3B). 
strongly suggest that induction of  RIS- 1, at least at ear- 
lier time points, may be specifically mediated by RA. 
First, RIS-1 mRNA was barely detectable in normal, 
vehicle- and RA-treated skin in which no measurable 
amounts of RA (_< 1 ng/gm wet wt tissue) were found. 
This was consistent with the notion that the presence 
of RA was required for RIS-1 gene activation in vivo. 
This RA-dependence  was also evidenced by a contin- 
ued rise in RIS- 1 transcript levels during the entire time 
course of  treatment. Secondly, the average concentra- 
tions of  RA detected in skin specimens after 6 h treat- 
ment in vivo were comparable to levels capable of acti- 
vating RAR/RXR receptors in cotransfection assays 
in vitro [21 ]. We found that the RA concentration was 
approximately 180-fold higher than EDso values for 
RAR-T, 60-fold higher than EDs0 for RAR-/3, 10-fold 
higher than EDso for RAR-/3, and equal to EDso for 
RXR-c~, all of  which are expressed at varying levels in 
human skin cells [7-9]. Thus, our data suggest, but do 
not prove, that RIS-1 gene might be directly regulated 
by RA/RA receptor complex interacting with potential 
cis-acting element(s) present in the RIS- 1 gene. Final- 
ly, RIS-1 mRNA induction was concomitant  with a 
marked increase in CRABP-II  mRNA levels in RA- 
treated skin. Increased CRABP-II  expression follow- 
ing RA treatment is consistent with the presence of 
RARE in the 5 ~ flanking region in the CRABP-I I  gene 
[31 ]. Although the precise role of CRABP-II  in mediat- 
ing the effects of RA in skin is unknown, recent in vivo 
studies have shown that CRABP-II  mRNA response 
is an indicator of retinoid activity in mouse [14] and 
human skin [28]. Therefore, it is interesting to note 
that RIS-1 mRNA activation coincides with both the 
accumulation of RA in skin layers and induction of a 
RA responsive gene, CRABP-II .  
To minimize the possibili ty of  cloning genes that 
might be induced by mild retinoid-induced irritation, 
the time points for construction of the RA~treated 
library were selected so as to allow for RA absorption 
and penetration through skin layers before the appear- 
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Fig. 4. Analysis ofhuman and mouse chromosomal DNA for homol- 
ogous sequences to RIS-1 cDNA. High molecular weight DNA from 
either mouse or human DNA was digested with various restriction 
enzymes shown at the top. Samples (10 #g) were electrophoresed, 
blotted and hybridized to a random-primed 32p-labeled RIS-I cDNA 
insert and washed at 02 × SSC, at 50 °C for 30 min. Size markers 
for mouse and human DNA are shown on the left and right, respec- 
tively. More stringent washes in 02 × SSC at 60 °C for 30 rain had 
no effects on the hybridization pattern of RIS-I to human DNA but 
totally abrogated the signal in mouse genomic DNA digest (data not 
shown). 
ance of  a clinical erythema. This was confirmed by 
histological evaluation of  several 4-mm punch biop- 
sies from the treated skin areas. Consistent with this 
approach, vehicle treatment of  skin for an extended 
period of time (4-24 h) did not stimulate RIS- 1 steady 
state mRNA levels. Our findings are also compatible 
with a recent study demonstrating that topical applica- 
tion of  RA and vehicle for up to 24 h did not induce 
erythema or any inflammatory response in human skin 
[28]. Prolonged vehicle treatment (48 h), however, 
modestly increased RIS-1 mRNA levels in some indi- 
viduals. Whether or not this increased RIS-1 mRNA 
level in vehicle-treated skin was simply related to occa- 
sional subcutaneous diffusion of  RA to adjacent tissue 
areas or was the result of  involvement of secondary 
mediators will require further investigation. For exam- 
ple, recent work has demonstrated that disruption of  
skin layers using agents such as sodium dodecyl sul- 
fate (SDS) [32], application of  organic solvents [33], 
and abrasion [34] produces an irritant response simi- 
lar to that observed in 4-day RA-treated skin [1, 28]. 
We have found no variations in RIS-1 transcript lev- 
els between vehicle and SDS treated human skin at 
several time points (manuscript in preparation). A bet- 
ter understanding of  possible vehicle effects on RIS- 
1 gene expression will require the analysis of  RIS-1 
induction in response to well-defined vehicle compo- 
nents. 
Both the induction of transcription and/or the accu- 
mulation of  message might be responsible for the ele- 
vated RIS- 1 mRNA levels seen in RA-treated skin. The 
rapid induction of RIS-1 mRNA in RA-treated skin 
in vivo is reminiscent of  other RA-induced genes some 
of which are trans-acting transcription factors. Several 
RA early response genes, Era-1/HOX 1.6 [18], MK-1 
[35], and z/f268 [36] have been isolated from vari- 
ous tissues and cell types but not from adult human 
skin. Because, the RIS-1 sequence is not homologous 
to these or any other widely distributed transcription 
factors such as AP-1 [37], its function, if any, is pre- 
sumably restricted to skin. Another possibility is that 
RIS-1 represents a skin-specific accessory molecule 
acting either alone or in concert with the R A W R X R  to 
regulate expression of  a distinct set of  RA target genes 
in skin. Theoretically, an indirect mechanism of RA 
responsiveness could result from the induction of  an 
intermediary activator protein such as RIS- 1. 
Based on the mRNA size of 0.6 kb, we would pre- 
dict RIS- 1 to encode a polypeptide of approximately 8 
to 9 kDa. Alignment of the peptide sequence derived 
from the partial RIS-1 cDNA exhibited a low homolo- 
gy (44%) with the consensus sequence of  the EF-hand 
type present in several calcium binding proteins [30]. 
The significance of this homology and whether or not 
RIS-1 protein actually binds Ca 2+ either in vivo or 
in vitro remains to be determined. Interestingly, we 
found that the partial RIS-1 cDNA was nearly identi- 
cal to psoriasin, a gene recently isolated from the skin 
of psoriasis patients [29]. Although psoriasin over- 
expression was previously suggested to be associated 
with the psoriasis phenotype, more recent work [38] 
has not confirmed the original report. Thus, it appears 
that the name 'psoriasin' might be a misnomer as tran- 
scripts for this gene are also found in other inflam- 
matory skin conditions [38]. Because our cDNA was 
truncated at the 5 r terminus, it was not possible to 
compare its amino terminal sequence with the corre- 
sponding region in psoriasin. It is noteworthy, how- 
ever, that the estimated size of  RIS- 1 mRNA (600 nt) 
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differs considerably from that of psoriasin which was 
reported to be 1000 nucleotides long [29]. One pos- 
sibility for this discrepancy is that the RIS-I mRNA 
reported here is a splicing variant derived from the 
psoriasin gene. However, because we observed only 
a single hybridizing band in the Northern blots, this 
does not appear to be likely. Another possibility is that 
RIS-1 and psoriasin are two related transcripts with 
divergent 5 ~ but identical 3' coding sequences. The 
presence of several hybridizing bands in the Southern 
blot of human genomic DNA (also see below) might 
sustain this idea. Alternatively, the variation in mRNA 
size for RIS- 1 and psoriasin may be simply due to the 
different methods used for their estimation in Northern 
blots. We always include RNA markers in our North- 
ern gels that are subsequently marked on filters and 
used for accurate sizing of an unknown mRNA. Thus, 
assuming that RIS-1 and psoriasin are the same gene 
products, a possibility we strongly favor, it is likely 
that our estimation of a mRNA of 600 nt is actually the 
correct size for RIS- 1/psoriasin. 
The fact that RIS-1 cDNA probe used in this work 
was only 209 nucleotides long implies that it proba- 
bly corresponds to one or two exons of RIS-1 gene. 
Therefore, the complex hybridization profile of RIS- 1 
in both human and mouse genomic DNA digests sug- 
gests either, (1) the existence of several RIS-1 pseu- 
dogenes in the genome, or (2) that RIS-1 belongs to a 
family of potentially RA-inducible genes, or perhaps 
both. 
Regardless of its function, the rapid induction and 
tissue-specific expression of RIS-1 in vivo, together 
with its RA-dependence, strongly suggest that RIS-1 
may be a target of RA action in skin. These findings 
implicate RIS-1/psoriasin as another gene similar to 
CRABP-II [28] which is known to be induced by top- 
ical RA and also elevated in psoriasis, a disease char- 
acterized by altered epidermal differentiation. Clearly, 
further work is needed to determine if RIS-l/psoriasin 
is a direct or indirect target of all-trans RA in skin. 
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